Breaking News, Collaborations & Alliances

Aptamer Group Collaborates with PinotBio

Will work together to develop new therapeutic drug conjugates.

Author Image

By: Charlie Sternberg

Associate Editor

Aptamer Group Limited, the developer of Optimer Therapeutics, and PinotBio (Gyeonggi-do, Korea), a clinical-stage oncology-focused biotechnology company, have entered into a strategic collaboration agreement to develop Optimer-drug conjugates for targeted drug delivery. The collaboration will combine Aptamer Group’s Optimer technology with PinotBio’s technology using the chemotherapeutic FL-118 compound with specific linker.   Optimer-drug conjugates offer uniquely specific targeting vehicles fo...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters